Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators by Mills, Edward J. et al.
Boston University
OpenBU http://open.bu.edu
Center for Global Health and Development Center for Global Health and Development Papers
2006-11-21
Adherence to HAART: A Systematic
Review of Developed and
Developing Nation
Patient-Reported Barriers and
Facilitators
Mills, Edward J., Jean B. Nachega, David R. Bangsberg, Sonal Singh, Beth Rachlis,
Ping Wu, Kumanan Wilson, Iain Buchan, Christopher J. Gill, Curtis Cooper.
"Adherence to HAART: A Systematic Review of Developed and Developing Nation
Patient-Reported Barriers and Facilitators" PLoS Medicine 3(11):e438. (2006)
https://hdl.handle.net/2144/3243
Boston University
Adherence to HAART: A Systematic Review
of Developed and Developing Nation
Patient-Reported Barriers and Facilitators
Edward J. Mills
1*
, Jean B. Nachega
1,2
, David R. Bangsberg
3
, Sonal Singh
1,2
, Beth Rachlis
4
, Ping Wu
5
,
Kumanan Wilson
1,6
, Iain Buchan
7
, Christopher J. Gill
8
, Curtis Cooper
1,9
1 Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada, 2 Department of International Health, Johns Hopkins Bloomberg School of Public
Health, Baltimore, Maryland, United States of America, 3 San Francisco General Hospital, AIDS Division, University of California San Francisco, San Francisco, California, United
States of America, 4 BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, British Columbia, Canada, 5 Canadian College of Naturopathic Medicine,
North York, Ontario, Canada, 6 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, 7 Evidence for Population Health Unit, University of Manchester,
Manchester, United Kingdom, 8 Center for International Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of
America, 9 Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Funding: This work was supported
by the Ontario HIV Treatment
Network (OHTN). EJM is supported
by the Canadian Institutes for Health
Research. JBN is supported by grants
AI005535901 and K23A106858201
from the US National Institutes of
Health. BR is supported by the British
Columbia Michael Smith
Foundation. KW is supported by
Canadian Institutes for Health
Research. DRB is supported by the
NIH (AA015287, MH54907, AI27763),
and The Doris Duke Charitable
Foundation. CC is supported by the
Ontario HIV Treatment Network.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Amir Attaran,
University of Ottawa, Ottawa,
Ontario, Canada
Citation: Mills EJ, Nachega JB,
Bangsberg DR, Singh S, Rachlis B,
et al. (2006) Adherence to HAART:
A systematic review of developed
and developing nation patient-
reported barriers and facilitators.
PLoS Med 3(11): e438. doi:10.1371/
journal.pmed.0030438
Received: December 8, 2005
Accepted: September 4, 2006
Published: November 21, 2006
Copyright:  2006 Mills et al. This is
an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: HAART, highly
active antiretroviral therapy
* To whom correspondence should
be addressed. E-mail: millsej@
univmail.cis.mcmaster.ca
A B S T R A C T
Background
Adherence to highly active antiretroviral therapy (HAART) medication is the greatest patient-
enabled predictor of treatment success and mortality for those who have access to drugs. We
systematically reviewed the literature to determine patient-reported barriers and facilitators to
adhering to antiretroviral therapy.
Methods and Findings
We examined both developed and developing nations. We searched the following databases:
AMED (inception to June 2005), Campbell Collaboration (inception to June 2005), CinAhl
(inception to June 2005), Cochrane Library (inception to June 2005), Embase (inception to June
2005), ERIC (inception to June 2005), MedLine (inception to June 2005), and NHS EED (inception
to June 2005). We retrieved studies conducted in both developed and developing nation
settings that examined barriers and facilitators addressing adherence. Both qualitative and
quantitative studies were included. We independently, in duplicate, extracted data reported in
qualitative studies addressing adherence. We then examined all quantitative studies addressing
barriers and facilitators noted from the qualitative studies. In order to place the findings of the
qualitative studies in a generalizable context, we meta-analyzed the surveys to determine a best
estimate of the overall prevalence of issues. We included 37 qualitative studies and 47 studies
using a quantitative methodology (surveys). Seventy-two studies (35 qualitative) were
conducted in developed nations, while the remaining 12 (two qualitative) were conducted in
developing nations. Important barriers reported in both economic settings included fear of
disclosure, concomitant substance abuse, forgetfulness, suspicions of treatment, regimens that
are too complicated, number of pills required, decreased quality of life, work and family
responsibilities, falling asleep, and access to medication. Important facilitators reported by
patients in developed nation settings included having a sense of self-worth, seeing positive
effects of antiretrovirals, accepting their seropositivity, understanding the need for strict
adherence, making use of reminder tools, and having a simple regimen. Among 37 separate
meta-analyses examining the generalizability of these findings, we found large heterogeneity.
Conclusions
We found that important barriers to adherence are consistent across multiple settings and
countries. Research is urgently needed to determine patient-important factors for adherence in
developing world settings. Clinicians should use this information to engage in open discussion
with patients to promote adherence and identify barriers and facilitators within their own
populations.
The Editors’ Summary of this article follows the references.
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Introduction
The introduction of antiretrovirals has been credited with
extending the life span of people living with HIV/AIDS [1].
However, treatment efficacy relies on access to treatment and
excellent adherence, which has proven to be a serious
challenge to those receiving highly active antiretroviral
therapy (HAART) [2,3]. The regimens are often complicated,
can require dietary restrictions, and may lead to adverse
effects [4]. Non-adherence to antiretroviral therapy in adult
populations has been shown to range from 33%–88%,
depending on how adherence is defined and evaluated [5].
Research indicates that consistently high levels of adherence
are necessary for reliable viral suppression [6,7] and
prevention of resistance [8], disease progression [9], and
death [10]. As successful HIV treatment requires exceptional
adherence to antiretroviral therapy, interventions to improve
and maintain adherence are needed.
Several studies have been conducted that examine factors
affecting adherence to HAART. We used a novel method-
ology to synthesize the information from these studies by
performing a systematic review on all the literature available
in this field using content analysis, particularly focusing on
the currently existing qualitative studies and examining their
generalizability through quantitative data. We examined both
developed and developing nation patient populations [11].
Methods
Search Strategy
We performed a systematic, all-language literature search
for all qualitative studies and quantitative surveys that
addressed barriers and motivators influencing adherence to
antiretroviral regimens in HIV-positive individuals.
We (EJM and BR) searched the following databases: AMED
(inception to June 2005), Campbell Collaboration (inception
to June 2005), CinAhl (inception to June 2005), Cochrane
Library (inception to June 2005), Embase (inception to June
2005), ERIC (inception to June 2005), MedLine (inception to
June 2005), and NHS EED (inception to June 2005).
Unpublished studies were also sought using the search terms
‘‘adherence’’ and ‘‘HIV’’ on Clinicaltrials.gov, the UK Na-
tional Research Register, and conference abstracts from
international conference Web sites: International AIDS
Society conferences (inception to 2005) and Conferences on
Retroviruses and Opportunitistic Infections (inception to
2005). Our search strategy combined terms that represented
attitudes, barriers, and anxieties. Our search vocabulary
included ‘‘HIV’’ or ‘‘AIDS’’, ‘‘compliance OR adherence’’,
‘‘factors OR determinant* OR barriers’’, ‘‘motivate* OR
facilit*’’, and ‘‘HAART OR antiretroviral*’’. The detailed
search strategy is available from the corresponding author
upon request. We supplemented this search by reviewing the
bibliographies of key papers.
Study Selection
Two members of the study team (BR and PW) independ-
ently reviewed the abstracts. Eligible studies met the following
criteria: (1) reported an original research study, (2) contained
content addressing barriers or facilitators to antiretroviral
adherence, and (3) were either a qualitative study or
quantitative survey. The studies were divided to represent
developed or developing nations, as according to the United
Nations Human Development Index (HDI) [12]. The HDI is a
composite index that measures a country’s average achieve-
ments in three basic aspects of human development:
longevity, knowledge, and a decent standard of living.
Data Extraction
Two reviewers (BR and PW) independently extracted data
and appraised both quality and content. From an initial
review of qualitative studies by BR and PW, a coding template
was iteratively developed to categorize key barriers to
adherence to HAART. The reviewers then conducted a
second review of the papers and identified whether they
contained the barriers present in the complete template. At
each stage of the data abstraction, the reviewers discussed the
studies to determine consensus regarding the identification
and coding of themes. We analyzed the themes presented in
the qualitative studies. After the initial viewing of the selected
articles, these themes were grouped into categories. Barriers/
facilitators fell under the following subheadings: (1) patient-
related, (2) beliefs about medication, (3) daily schedules, and
(4) interpersonal factors/relationships. To determine the
extent to which these themes exist in the wider communities
of developed and developing nations, the reviewers then
abstracted data from the survey studies to determine if the
issues addressed in the qualitative studies had been asked
about in the surveys. We abstracted data on the prevalence of
the issues as reported in the surveys.
We extracted data on the quality of both qualitative and
quantitative studies using pre-determined criteria for quality.
We previously reported our rationale for assessing the quality
of qualitative studies and in this study have extended our
quality assessment to examine quantitative surveys [13].
Although no formal criteria exist for appraising the quality
of surveys, we a priori determined that the following criteria
are important across surveys: 1) the survey included members
of the target community in the preparation of the survey tool,
2) the survey instrument was assessed for face validity, 3) the
Figure 1. Flow Chart of Studies Included in Review
doi: 10.1371/journal.pmed.0030438.g001
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Table 1. Study Characteristics
Reference Country Population Focus of Study Setting Notes
Abel, 2003 [18] US n ¼ 6; 100% women; (2
African-American, 1 His-
panic, 3 white)
Factors that influence adher-
ence to ART were explored
from perspective of women
Clinic
Adamian, 2004 [30] US n ¼ 20; 14 men/6 women
(18 African-American, 1
white, 1 multiracial)
Pilot study to assess patients’
perceptions of and attitudes to-
ward the motivational inter-
viewing session
Clinic Study also tested and as-
sessed motivational inter-
viewing model
Adam, 2003 [45] Canada n ¼ 35; 31 men/ 4 wo-
men (no ethnicity info gi-
ven)
Paper examines difficulties with
ART adherence particularly re-
lated to dosing schedules and
food prohibitions with the
structure of everyday lives
Clinic
Aversa, 1996 [46] US n ¼ 99; 74 men/24 wo-
men (71% white: 25%
African-American: 4% His-
panic)
Study examines variables re-
lated to alteration of ART regi-
mens, independent of medical
advice
Via telephone
Barton Laws, 2000 [31] US n ¼ 25 (sub-sample from
group of 61); 17 men/8
women (9 Euro-American,
3 African-American, 12
Latino/Latina, 1 Portug-
ese)
Describe patients’ medication-
taking behaviour and factors
related to non-adherence.
Homes, hospitals, residen-
tial substance abuse
treatment programs, and/
or offices
Brigido, 2001 [47] Brazil n ¼ 182; 126 men/56 wo-
men
To assess if adherence to anti-
retroviral medication would
correlate to clinical and labora-
tory outcomes
Clinic
Golin, 2002 [19] US n ¼ 24; 16 men/8 women
(12 African-American: 12
white)
To understand barriers to ART
adherence faced by patients liv-
ing with HIV in the southeast-
ern US
Clinic
Goode, 2003 [48] Australia n ¼ 18 (11 boys/7 girls)
(no ethnicity info given)
To examine beliefs about pe-
diatric HAART from the care-
givers’ perspective in addition
to examining these beliefs in
relation to the day-to-day lives
of children and their families
Telephone interview Ten families were urban,
and eight were rural; rural
families had more difficulty
integrating morning dose;
in addition, there was a
lower level of support com-
pared with urban families
Graney, 2003 [32] US n ¼ 67; 44 men/13 wo-
men (82% African-Ameri-
can)
Study seeks to document rela-
tionships between HIV/AIDS
medication regimen adherence
and characteristics of the regi-
men itself, social factors, psy-
chological factors, and health-
care practitioner factors
Inner-city clinic
Hammami, 2004 [44] Belgium n ¼ 11; caregivers; 8
mother; 1 adoptive par-
ent; 2 self-care; age 0.25–
18.75 y
To understand adherence beha-
viour in a pediatric population,
as reported by caregivers
Medical center
Hills, 2003 [33] US n ¼ 78 (no demographic/
ethnicity given specific to
study; only general clinic
population)
Explore patterns and explana-
tions of adherence to antiretro-
viral therapies from the pa-
tients’ perspective
Clinic
Johnston-Roberts, 2003 [108] US n ¼ 20; 100% women
(50% Hispanic, 35% Afri-
can-American, 15% white)
Explore, using HIV-positive wo-
men’s own recollections col-
lected in diary format, how and
why women intentionally fail to
adhere to ART
Journal entry Followed one entry (a 42–
y-old Hispanic woman)
Johnston-Roberts, 2002 [34] US n ¼ 28; 15 men/13 wo-
men (46% white, 36%
African-American, 14%
Hispanic, 4% other)
Explore the connections be-
tween HIV-positive patients’ ad-
herence to antiretroviral medi-
cation regimens and their
beliefs about and satisfaction
with their primary care physi-
cians
Clinic
Johnston-Roberts, 2000 [54] US n ¼ 38; 100% women
(50% Hispanic, 35% Afri-
can-American, 15% white)
Explore, from HIV-positive wo-
men’s own perspectives, the
barriers they faced in adhering
to combination antiretroviral
therapies
Journal entries
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Table 1. Continued.
Reference Country Population Focus of Study Setting Notes
Ka’opua, 2004 [53] US n ¼ 80; 57 men/23 wo-
men (40 Native Hawaiian,
40 white)
To understand HAART adher-
ence among Native Hawaiians,
a group with historic difficulty
in using Western health-care
services because of cultural
conflict
AIDS center Native Hawaiians signifi-
cantly more likely than
white participants to view
family support as a critical
strategy for adherence
Kemppainen, 2004 [49] US n ¼ 46; 38 men/8 women
(12 African-American, 24
white, 5 Hispanic, and 5
mixed)
To identify factors and circum-
stances that influence the abil-
ity of persons with HIV/AIDS
and severe mental illness to
comply with ART regimens
Day care program to
treat HIV and severe
mental illness
Non-white persons and
those living alone were
more likely to rely on the
use of reminders and cues
Klitzman, 2004 [35] US n ¼ 152; 96 men/56 wo-
men (47 white, 40 Latino/
Latina, 60 African-Ameri-
can, 5 other)
To understand whether and
how HAART affects views and
patterns of disclosure and how
disclosure interacts with treat-
ment decisions
Clinic
Malcolm, 2003 [36] US n ¼ 44; 28 men/16 wo-
men (17 ‘‘people of col-
or’’/ 27 white)
Examine the health-related atti-
tudes and beliefs of HIV/AIDS
patients with excellent adher-
ence to HAART and how they
differ from those of patients
with suboptimal adherence
Clinic
Meystre-Agustoni, 2000 [37] Switzerland n ¼ 37; 25 men/12 wo-
men (no ethnicity infor-
mation given)
Explore patients’ perceptions of
HAART
Clinic
Miller, 2002 [20] US n ¼ 30; 23 men/7 women
(21 Latino, 7 African-
American, 2 white)
Assessed barriers to adherence
to antiretroviral regimens by
conducting focus groups and
asking patients about their pre-
ferences for different aspects of
antiretroviral regimens
Clinic
Misener, 1998 [21] US n ¼ 22; 100% women (18
African-American, 4 white)
To describe the influences af-
fecting decisions made by wo-
men in the southern US to ac-
cept and adhere to
antiretroviral therapy
Social service agency
Murphy, 2003 [23] US n ¼ 81; 45 men/36 wo-
men (22% Central Ameri-
can, 61% Mexican, 6%
Mexican-American or Chi-
cano, 1% South Ameri-
can, 4% mixed, and 5%
other)
Three aims: (1) to determine
what barriers impede adher-
ence, (2) what strategies facili-
tate adherence, and (3) investi-
gate the health-care provider–
patient relationship and how it
may affect adherence
Clinic Language barriers reported;
use of translators not al-
ways seen as a sufficient re-
medy
Murphy, 2000 [22] US n ¼ 39; 27 men/12 wo-
men (3% Asian/Pacific Is-
lander, 44% African-Amer-
ican, 6% Latino, 3%
Native American, 39%
white, 6% other or
mixed)
Determine what strategies facil-
itate adherence, determine
what barriers prevent adher-
ence, and investigate the
health-care provider–patient re-
lationship and how it may af-
fect adherence
Clinic
Oggins, 2003 [38] US n ¼ 62; 40 men/22 wo-
men (21 African-Ameri-
can, 7 Asian, 2 Haitian, 12
Latino/Latina, 9 European
American, 11 Native
American)
To explore the reasons for low
adherence to HIV-medication
regimens among ethnic minor-
ity groups
Private homes, health
agencies, or via tele-
phone
Study indicates that non-
adherence may be asso-
ciated with important mis-
conceptions about HIV,
confusion about relation-
ship between HIV and AIDS
etc.
Powell-Cope, 2003 [24] US n ¼ 24; 100% women (22
African-American, 2 white)
To obtain complementary data
on the complex set of beliefs,
attitudes, and behaviours that
are related to adherence in in-
digent, substance-abusing wo-
men.
Clinic Apart from qualitative focus
groups, quantitative surveys
were also used
Proctor, 1999 [25] US n ¼ 39; 27 men/12 wo-
men (19 white, 16 Afri-
can-American, 4 Hispanic)
To understand the barriers to
adherence to HAART faced by
people living with HIV/AIDS
University medical centers
and clinics
Secondary objective of
study was to develop a sur-
vey questionnaire based on
data collected
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Table 1. Continued.
Reference Country Population Focus of Study Setting Notes
Reback, 2003 [39] US n ¼ 23; 100% men (87%
white, 19% Latino, 4%
Native American)
To understand the meaning of
reported HIV medication adher-
ence among gay and bisexual
men who are dependent on or
abuse methamphetamine
Treatment center
Remien, 2003 [50] US n ¼ 110; 70 men/40 wo-
men (33% white, 31%
Hispanic, 43% African-
American, 2% other)
To present qualitative data re-
lating to adherence to antire-
troviral therapy for HIV disease
from a diverse sample in four
US cities
Clinics and community-
based service organiza-
tions
Richter, 2002 [26] US n ¼ 33; 100% women,
100% African-American
To examine attitudes and be-
liefs of African-American wo-
men of child-bearing age living
with HIV, about pregnancy and
antiretroviral therapy
Community-based organi-
zations
Ryan, 2003 [40] US n ¼ 27; 21 men/6 women
(64% African-American)
Exploratory study examines the
contextual factors that lead to
episodic non-adherence to
HAART
Not specified Population consisted of
past and current drug users
Sankar, 2002 [51] US n ¼ 15; 100% women
(100% African-American)
To identify sources of authority
that either promote or discou-
rage adherence; also, to explore
how women resolve conflicts
between conflicting sources of
influence
Clinic
Schilder, 2001 [27] Canada n ¼ 47; 27 gay men, 10
bisexual men, 10 trans-
gendered men (16 First
Nations, 31 white, 1
Asian, 1 Latino, 1 French
Canadian, 1 Jewish)
To characterize the relationship
between identity and health-
care experiences (including ART
utilization) among HIV-positive
sexual minority males
Community agencies and
hospitals
Stone, 1998 [28] US n ¼ 56; 28 men/28 wo-
men (16 African-Ameri-
can, 12 Latino/Latina, 28
white)
To gather qualitative data re-
garding HIV/AIDS patients’ per-
spectives about HIV-1 protease
inhibitors and about their ex-
periences taking and adhering
to regimens containing PIs
Health centers and hospi-
tal clinics
Weiser, 2003 [52] Botswana n ¼ 109; 54 men/55 wo-
men (no ethnicity infor-
mation given)
To improve antiretroviral ther-
apy treatment delivery, social,
cultural, and structural determi-
nants of treatment adherence
were studied
Clinics
Westerfelt, 2004 [29] US n ¼ 21; 100% men, 100%
white
To explore adherence issues
among HIV-positive individuals
to provide information to de-
sign interventions to help indi-
viduals achieve higher rates of
adherence to ART
Immunology center Population reflects state
epidemic
Wilson, 2002 [41] US n ¼ 66; 90% men/10%
women (50% white,
27.3% African-American,
10.6% Hispanic, 4.5% Na-
tive American, 1.5% Filipi-
no, 4.5% other)
To explain how ethnically di-
verse men and women infected
with HIV manage their interact-
ing symptom clusters and med-
ication side effects as well as
their treatment adherence
choices
Clinic
Witteveen, 2002 [42] The Netherlands n ¼ 27; 16 men/11 wo-
men (ethnicity not given)
To provide better insights to
the extent of adherence to
HAART in ‘‘hard drug’’ users
Clinic
Wood, 2004 [43] US n ¼ 36; 100% women (19
Latina, 10 Euro-American,
5 African-American, 2
Cape Verdean)
The study seeks to better un-
derstand the patterns, barriers,
and facilitators to medication
adherence in women caring for
children
Health agency
doi:10.1371/journal.pmed.0030438.t001
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survey population was randomly selected, 4) a rationale for
determining the response rate was provided, and 4) the
investigators attempted to contact non-responders. We did
not propose a cut-off score for higher-quality surveys versus
lower-quality surveys.
Statistical Analysis
We measured chance-adjusted inter-rater agreement for
eligibility using the j statistic. EM and PW conducted all
statistical analyses. When information on proportions was
available in the quantitative studies, we first stabilized the
variances of the raw proportions (r/n) using a Freeman-
Tukey-type arcsine square-root transformation [14], and then
conducted weighted analysis of studies using methods
described by Fleiss [15]. The pooled proportion is calculated
as the back-transform of the weighted mean of the trans-
formed proportions, using inverse arcsine variance weights
for the fixed-effects model and DerSimonian-Laird weights
for the random-effects model. The random-effects model
recognizes that the studies are a sample of all potential
studies and incorporates an additional between-study com-
ponent to the estimate of variability [16]. Thus, larger studies
with smaller variances have relatively more impact on the
final estimate. We present the weighted mean with 95%
confidence intervals, with lower confidence intervals trun-
cated at zero. The I2 statistic was calculated as a measure of
Table 3. Quality Criteria for Survey Studies
Countries Reference Population Involvement
in Survey Development
Face
Validity
Random
Sampling
Response Rate
Calculations
Attempt to Contact
Non-Responders
Developed countries Ammassari, 2001[ [56] 
Brook, 2001[ [55] 
Catz, 2000 [58] 
Chesney, 2000 [59]  
Eldred, 1998[ [61]   
Erlen, 2002 [62]
Ferguson, 2002 [4] 
Gibb, 2003 [65] 
Giacomet, 2003 [64]
Harzke, 2004 [66] 
Heckman, 2004 [67]  
Horne, 2004 [69]  
Johnson, 2003 [70]  
Kalichman, 1999 [71] 
Kerr, 1999 [72]  
Kleeberger, 2001 [73]  
Marhefka, 2004 [74]  
Moatti, 2000 [75] 
Mohammed, 2004 [76]  
Mostashari, 1998 [79] 
Muma, 1995[80]  
Murphy, 2003[81]  
Nieuwkerk, 2001[83] 
Palmer, 2003 [84]  
Reddington, 2000 [86] 
Reynolds, 2004 [87]  
Savini, 2003 [88] 
Schneider, 2004[89]  
Siegel, 2000[90] 
Simoni, 2002[91]  
Spire, 2002[92]  
Stein, 2000[93] 
Tucker, 2004[95]  
Wagner, 2004[97]  
Walsh, 2001[98]  
Weidle, 1999[99] 
Wilson, 2001[100]   
Developing countries Byakika-Tusiime J, 2005[57]  
Cupsa, 2000[60] 
Fassinou, 2004[63] 
Hofer, 2004[68] 
Molassiotis, 2002[77]  
Monreal, 2002[78] 
Nachega, 2004[82]   
Pinheiro, 2002[85]  
Stout, 2004[94] 
van Oosterhout, 2005[96] 
 indicates that the methodological item was reported in the original text.
doi:10.1371/journal.pmed.0030438.t003
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the proportion of the overall variation in the meta-analyses
that was attributable to between-study heterogeneity [17].
Results
Study Selection and Characteristics
The primary literature search produced 228 studies. There
was near-perfect agreement between EJM and BR on
choosing the 115 applicable studies from the reviewed
abstracts (K  0.8). Of these, 31 were excluded as they were
either not original studies or did not examine factors that
influence adherence to antiretroviral therapy. The remaining
84 studies were included in our analysis (see Figure 1). There
was perfect agreement on the final studies selected between
BR and PW. All studies were published in English.
Thirty-seven of the studies were qualitative (see Tables 1
and 2). Twelve used focus groups (total number of patients, n
¼ 415) [18–29], 15 used semi-structured interviews (n ¼ 729)
[30–44], and nine used open-ended questioning (n ¼ 694)
[45–53] to explore barriers and facilitators to adherence.
One study employed a writing intervention to solicit barriers
and motivators to adherence [54]. The 47 remaining studies
employed a quantitative methodology (surveys) and used
structured questionnaires or structured interviews (total n ¼
12,902 [55]) [4,56–100] to determine potential factors. Table
3 displays the quality criteria results for the quantitative
studies. No studies reported following up with non-respond-
ers to the surveys. Of the total sample of eligible studies, 72
were conducted in developed countries [4,18–25,30–39,44–
4 6 , 4 8 – 5 0 , 5 3 – 5 6 , 5 8 , 5 9 , 6 1 , 6 2 , 6 4 – 6 7 , 6 9 – 7 6 , 7 9 –
81,83,84,86,87,108], and 12 in developing nations
[47,52,57,60,63,68,77,78,82,85,94,96]. Fifty-six were from the
Un i t ed S t a t e s [ 4 , 1 8–26 , 2 8 , 3 0 –36 , 3 8–40 , 46 , 4 9 –
51,53,54,58,59,61,62,66,67,70,71,73,74,76,79–81,84,86,88–
91,93,95,108], three from Canada [27,45,72], three from the
United Kingdom [55,69,98], two from Italy [56,64], two from
France [75,92], two from The Netherlands [42,83], and one
each from Australia [48], Switerland [37], and Belgium [44].
Two studies were multinational [65,87]. The studies con-
ducted in developing countries included four from Brazil
[47,68,78,85], and one each from Uganda [57], Cote d’Ivoire
[63], South Africa [82], Malawi [96], Botswana [52], Costa Rica
Figure 2. Barriers Reported in Developed Countries
doi:10.1371/journal.pmed.0030438.g002
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[94], Romania [60], and China [77]. Tables 4 and 5 outline the
factors affecting HAART adherence reported by HIV-
positive individuals from developed and developing coun-
tries as determined by the qualitative studies.
Barriers and Facilitators Listed by Patients in Developed
Countries: Themes from Qualitative Studies
Barriers. Thirty-three individual themes of barriers were
recorded in 34 qualitative studies (see Table 4).
Patient-related: Thirteen barriers were patient-related and
included: a fear of disclosure and wanting to avoid taking
medications in public places (23/34) [18–20,22–25,27–29,31–
33,35–37,40,42,44,45,49–51,108]; feeling depressed, hopeless,
o r ove rwhe lmed (18 /34 ) [ 19 , 23–26 ,29 , 31 , 33 , 36 ,
40,41,43,45,46,49,50]; having a concurrent addiction (14/34)
[23,24,27,31,33,36,39–42,49–51,81]; and forgetting to take
medication at the specified time (11/34) [20,24,25,28,31–
33,37,40,44,50]. Other barriers include: being suspicious
of treatment/medical establishment (9/34) [21,26,35,36,38,
41,42,50,51]; wanting to be free of medications or preferring
a natural approach (10/34) [20,21,29,31,32,37,44,50,54,108];
feeling that treatment is a reminder of HIV status (8/34)
[18,32,38,39,41,43,49,54]; wanting to be in control (7/34)
[28,31,37,38,41,54,108]; not understanding treatment instruc-
tions (5/34) [31,33,36,38,42]; still having doubt or not being
able to accept HIV status (5/34) [18,33,42,44,51]; and a lack of
self-worth (4/34) [35,43,44,51]. Financial constraints [31,42,46],
being homeless [40,42], and having other concurrent illnesses
affecting adherence were also cited.
Beliefs about medication: There were eight reported
barriers pertaining to beliefs/perceptions about medications.
Some common barriers in this category included: side effects
(either real or anticipated) (27/34) [18,20,21,23–32,35,37,38,41–
46,48–50,54,108]; complicated regimens (12/34) [18,22,23,26–
28,32,42,48–50,54]; and the taste, size, dosing frequency, and/or
pill count (12/34) [18,20,23–25,29,45,48–50,54]. In nine studies,
when individuals prescribed HAART felt healthy, adherence
was often negatively affected [22,24,25,29,32,33,38,43,44].
Other barriers included: doubting the efficacy of HAART (7/
34) [21,23,25,26,42,45,46]; having a decreased quality of life (6/
Table 5. Facilitators Reported in Qualitative Studies
Qualitative Studies Patient Variables Beliefs about Medication
Self Efficacy/
Self Meaning
Medication Takes
Priority over
Substance Abuse
Accepted HIV Status/
Learned to Manage
Seeing
Positive
Results
Understand
Need for
Compliance
Belief in
Efficacy of Drugs/
Faith in Treatment
Simple
Regimen
Abel, 2003[18]    
Adamian, 2004[30] 
Adam, 2003[45]   
Aversa, 1996[46]
Barton Laws, 2000[31]
Golin, 2002[19]  
Goode, 2003[48]
Graney, 2003[32]    
Hammami, 2004[44]    
Hill, 2003[33]
Johnston Roberts, 2003[108]
Johnston Roberts, 2002[34]
Johnston Roberts, 2000[54]
Ka’opua, 2004[53]  
Kemppainen, 2004[49]    
Klitzman, 2004[35]
Malcolm, 2003[36]   
Meystre-Agustoni, 2000[37]
Miller, 2002[20]
Misener, 1998[21] 
Murphy, 2003[23]    
Murphy, 2000[22] 
Oggins, 2003[38]
Powell-Cope, 2003[24]   
Proctor, 1999[25]
Reback, 2003[39]
Remien, 2003[50]   
Richter, 2002[26]   
Ryan, 2003[40] 
Sankar, 2002[51]  
Schilder, 2001[27]
Stone, 1998[28]    
Westerfelt, 2004[29]  
Wilson, 2002[41]  
Wittevee, 2002[42]    
Wood, 2004[43]
doi:10.1371/journal.pmed.0030438.t005
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34) [20,24,25,38,42,46]; uncertainty of long-term effects (6/34)
[30,32,45,46,48,49]; and unwanted changes in body image (5/34)
[18,28,37,45,54].
Daily schedules: Nine common barriers were related to
daily schedules and included: disruptions in routine or having
a chaotic schedule (16/34) [19,22,23,25,27,30,37,39–45,54,108];
finding HAART too inconvenient or difficult to incorporate
(14/34) [19,20,27–29,31,32,37,38,41,44,46,48,54,108]; and diffi-
culties coordinating adherence with work, family, or care-
giving responsibilities (11/34) [18,20,24,27,28,31,32,37,45,54].
Individuals in seven studies found it difficult to balance the
numerous strict dietary requirements associated with
HAART [18,19,22,25,30,39,45]. Six studies cited sleeping
through a dose [19,29,31,39,40,49]. Other barriers included:
being away from home and not bringing medication (6/34)
[24,31,33,39,40,42]; being too distracted or busy (5/34)
[24,29,33,40,51]; and having no time to refill prescriptions,
or other pharmacy-related problems (4/34) [22,24,25,31].
Finally, four studies described difficulties with a particular
dose, particularly the middle-of-day or early-morning dose
[19,29,42,48].
Interpersonal relationships: Interpersonal relationships
can affect adherence behaviors. Twelve studies noted a lack
of trust or a dislike of a patient’s health-care provider as an
impediment to adherence [21–24,27,31,34,36,38,42,49,50].
Ten studies noted social isolation [23,25,33,36,42,44,48–51].
Nine studies noted negative publicity regarding HAART or
the medical establishment [21,28,35,36,38,44–46,51]. Finally,
five studies noted that having a discouraging social network
often deterred patients from successful adherence (5/34)
[21,23,28,35,45].
Facilitators. Patient-related: Fourteen factors facilitating
successful adherence to HAART were abstracted. Patient-
related facilitators included having self-worth (15/23)
[19,23,26,28,29,32,36,41,42,44,45,49–51,53], medication taking
priority over substance use (4/23) [23,36,40,42] and seeing
positive results when adhering to HAART (6/23)
[24,26,28,32,45,50]. Also, those patients who had accepted
their HIV-seropositivity reported improved adherence (8/23)
[18,28,29,32,41,44,49,51].
Beliefs about medication: The most common motivator (12/
23) to adherence is a belief in the efficacy of HAART and
Table 5. Extended.
Qualitative Studies Daily Schedules Interpersonal Relationships
Having a Fixed
Routine
Use of Reminder
Tools
Having
Social Support/
Open Disclosure
Good Relationship
with Provider
Living for
Someone
Part of
Decision
Making
Family/
Friends
Help Remind
Abel, 2003[18]     
Adamian, 2004[30]   
Adam, 2003[45]   
Aversa, 1996[46]
Barton Laws, 2000[31]
Golin, 2002[19]    
Goode, 2003[48]
Graney, 2003[32]   
Hammami, 2004[44]    
Hill, 2003[33]
Johnston Roberts, 2003[108] 
Johnston Roberts, 2002[34]  
Johnston Roberts, 2000[54]
Ka’opua, 2004[53]   
Kemppainen, 2004[49]    
Klitzman, 2004[35]  
Malcolm, 2003[36]    
Meystre-Agustoni, 2000[37]
Miller, 2002[20]
Misener, 1998[21]  
Murphy, 2003[23]      
Murphy, 2000[22]     
Oggins, 2003[38]
Powell-Cope, 2003[24] 
Proctor, 1999[25]
Reback, 2003[39]
Remien, 2003[50]   
Richter, 2002[26]   
Ryan, 2003[40]    
Sankar, 2002[51]   
Schilder, 2001[27]
Stone, 1998[28]  
Westerfelt, 2004[29] 
Wilson, 2002[41]
Wittevee, 2002[42]    
Wood, 2004[43]
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‘‘having faith’’ in the treatment [18,19,21–24,42,44,45,49,50,53].
Other motivators included understanding the need for strict
compliance (9/23) [18,24,26,28,30,32,36,42,44], and having a
simple regimen (3/23)[18,21,49].
Daily schedules: Twelve studies reported learning to balance
HAART with daily schedules as a facilitator of adherence.
Having a routine in which taking antiretrovirals could be easily
incorporated (11/23) [22,23,26,30,32,36,40,42,44,45,49], and
making use of reminder tools (7/23) [18,22,23,40,42,44,49] are
both reported to be effective tools for optimizing adherence.
Interpersonal relationships: Positive interpersonal relation-
ships were reported as necessary for successful adherence.
Having a trusting relationship with a health-care provider was
reported as a facilitator of adherence in 17 studies [18,19,21–
24,28,29,32,34,36,42,44,45,49–51,53,108]. In addition, openly
disclosing HIV status to family and friends and having a strong
support network was reported as influential to adherence (18/
23) [18,19,22,23,26,30,32,35,36,40,42–45,49–51,53]. Other mo-
tivators included: living for someone, especially, children (9/
23) [19,21,23,26,28,43,45,50,51]; being actively involved in
treatment decision making (4/23) [18,22,34,36]; and using
friends and family as reminders (6/23) [18,19,23,35,40,53].
Table 6. Barriers Reported in Quantitative Studies (Surveys)
Countries Reference Patient Variables
Fear of
Disclosure
Feeling
Over-
whelmed
Concurrent
Substance
Abuse
Simply
Forgot
Suspicions
of Treatment
Want to be
Free of Meds/
Feel Normal/
Holistic Approach
Want to
Maintain
Control
Developed countries Ammassari, 2001[56] 
Brook, 2001[55] 
Catz, 2000[58]  
Chesney, 20[59]   
Eldred, 1998[61]   
Erlen, 2002[62]   
Ferguson, 2002[4]  
Gibb, 2003[65] 
Giacomet, 2003[64]
Harzke, 2004[66]  
Heckman, 2004[67]  
Horne, 2004[69]   
Johnson, 2003[70] 
Kalichman, 1999[71]    
Kerr, 1999[72]   
Kleeberger, 2001[73]   
Marhefka, 2004[74]  
Moatti, 2000[75] 
Mohammed, 2004[76]     
Mostashari, 1998[79]
Muma, 1995[80]  
Murphy, 2003[81]   
Nieuwkerk, 2001[83] 
Palmer, 2003[84]   
Reddington, 2000[86]  
Reynolds,2004[87]   
Savini, 2003[88]
Schneider, 2004[89]
Siegel, 2000[90]
Simoni, 2002[91]   
Spire, 2002[92]   
Stein, 2000[93]    
Tucker, 2004[95] 
Wagner, 2004[97]
Walsh, 2001[98]     
Weidle, 1999[99] 
Wilson, 2001[100] 
Developing countries Byakika-Tusiime, 2005[57] 
Cupsa, 2000[60] 
Fassinou, 2004[63]
Hofer, 2004[68]
Molassiotis, 2002[77]   
Monreal, 2002[78] 
Nachega, 2004[82] 
Pinheiro, 2002[85]  
Stout, 2004[94] 
van Oosterhout, 2005[96] 
doi:10.1371/journal.pmed.0030438.t006
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Common themes from surveys and quantitative studies.
Figure 2 displays the pooled results of studies assessing
barriers and reporting proportions of responders. Table 6
displays the surveys that did inquire of the issues addressed in
the qualitative studies. There were three barriers described in
qualitative reports but not in the quantitative studies. These
were: having suspicions regarding HAART, wanting to be in
control, and doubting or having difficulty accepting one’s
HIV status.
Eight quantitative studies reported facilitators to adherence
(see Table 7). Four themes for facilitation of adherence were
mentioned in the qualitative studies that were not discussed in
the relevant quantitative studies (i.e., having medication take
priority over substance abuse, having a simple regimen, using
reminder tools, and living for someone).
Barriers Listed by Patients in Developing Countries:
Themes from Qualitative Studies
As there were only two studies identified, we describe the
findings here. Eighteen specific barriers are cited in two
studies [47,52].
Patient-related: The most common patient-related barriers
were: having a co-existing substance addiction, simply
forgetting, and financial constraints [47,52]. Other barriers
affecting adherence incorporated: a fear of disclosure [52];
Table 6. Extended.
Countries Reference Patient Variables
Treatment
Reminder of
HIV Status
Don’t
Understand
Treatment/
Misinformed
Doubt HIV
Status/
Haven’t
Accepted It
Financial
Constraints
No Self
Worth/
Doubt Ability
to Adhere
Homeless/
Other
Concurrent
Illness
Prefer
Holistic/
Natural
Approach
Developed countries Ammassari, 2001[56]
Brook, 2001[55] 
Catz, 2000[58]  
Chesney, 20[59]
Eldred, 1998[61]  
Erlen, 2002[62]
Ferguson, 2002[4]   
Gibb, 2003[65]
Giacomet, 2003[64]
Harzke, 2004[66]
Heckman, 2004[67]
Horne, 2004[69] 
Johnson, 2003[70] 
Kalichman, 1999[71] 
Kerr, 1999[72]
Kleeberger, 2001[73]
Marhefka, 2004[74]
Moatti, 2000[75]
Mohammed, 2004[76] 
Mostashari, 1998[79] 
Muma, 1995[80]   
Murphy, 2003[81]  
Nieuwkerk, 2001[83]
Palmer, 2003[84]
Reddington, 2000[86]  
Reynolds,2004[87]
Savini, 2003[88] 
Schneider, 2004[89]
Siegel, 2000[90]  
Simoni, 2002[91] 
Spire, 2002[92]
Stein, 2000[93]
Tucker, 2004[95]
Wagner, 2004[97]
Walsh, 2001[98]  
Weidle, 1999[99] 
Wilson, 2001[100] 
Developing countries Byakika-Tusiime, 2005[57]   
Cupsa, 2000[60]  
Fassinou, 2004[63] 
Hofer, 2004[68] 
Molassiotis, 2002[77]
Monreal, 2002[78] 
Nachega, 2004[82]
Pinheiro, 2002[85]
Stout, 2004[94]
van Oosterhout, 2005[96] 
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difficulty understanding both treatment instructions; the
need for compliance [47]; and the presence of concurrent
diseases or illnesses, including malnutrition [52].
Beliefs about medication: Barriers reflective of patient
beliefs regarding antiretrovirals included: side effects (either
real or anticipated) [52]; complicated regimens [52]; the taste,
size, and frequency of dosing [52]; having doubts about
HAART efficacy [47]; feeling fine or healthy [52]; a decreased
quality of life while taking medications, or feeling too sick
[52]; and being uncertain about potential long-term effects of
HIV treatment [47].
Daily schedules: Trouble incorporating work and family
responsibilities with HAART was seen as a barrier to
adherence in both studies. Traveling long distances to receive
treatment was common, and not surprisingly, transportation
difficulties were often reported to be a major hindrance to
adherence (2/2). Other barriers included running out of
medications or having an irregular supply [52]; being away
from home [52]; and being too busy or distracted to properly
comply [52].
No studies mentioned interpersonal relationships as a
barrier to adherence in this population.
No facilitators to adherence were discussed in any study in
a developing nation setting.
Table 6. Extended.
Countries Reference Beliefs about Medication
Side
Effects
(Real or
Anticipated)
Regimens
Compli-
cated/
Confusion
Taste/Size/
Number/
Frequency
of Dosing
Not
Convinced
of Efficacy
Feel
Fine/
Healthy
Uncertainty
of Long-
Term
Effects
Decreased
Quality of
Life/Feel
Worse
Unwanted
Changes
in Body
Image
Too
Toxic/
Harmful
Developed countries Ammassari, 2001[56]   
Brook, 2001[55]  
Catz, 2000[58]     
Chesney, 20[59]    
Eldred, 1998[61]     
Erlen, 2002[62] 
Ferguson, 2002[4]      
Gibb, 2003[65] 
Giacomet, 2003[64]  
Harzke, 2004[66]   
Heckman, 2004[67]  
Horne, 2004[69]   
Johnson, 2003[70]   
Kalichman, 1999[71]    
Kerr, 1999[72]  
Kleeberger, 2001[73]     
Marhefka, 2004[74]    
Moatti, 2000[75] 
Mohammed, 2004[76]   
Mostashari, 1998[79]
Muma, 1995[80]    
Murphy, 2003[81]      
Nieuwkerk, 2001[83] 
Palmer, 2003[84]      
Reddington, 2000[86]   
Reynolds,2004[87]     
Savini, 2003[88]   
Schneider, 2004[89]
Siegel, 2000[90]    
Simoni, 2002[91]     
Spire, 2002[92]  
Stein, 2000[93]   
Tucker, 2004[95]  
Wagner, 2004[97] 
Walsh, 2001[98]    
Weidle, 1999[99]   
Wilson, 2001[100]     
Developing countries Byakika-Tusiime, 2005[57]  
Cupsa, 2000[60]  
Fassinou, 2004[63]  
Hofer, 2004[68]  
Molassiotis, 2002[77]     
Monreal, 2002[78]  
Nachega, 2004[82]  
Pinheiro, 2002[85]     
Stout, 2004[94]
van Oosterhout, 2005[96] 
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Themes from surveys and quantitative studies. Ten surveys
were found in developing settings (see Figure 3). No
quantitative study enquired of difficulties with morning or
afternoon doses, work and family responsibilities, or listed
inconvenience as a barrier.
Discussion
To our knowledge, this is the first systematic review to
examine the concerns of HIV patients to maintaining
adherence. We found that fear of disclosure, forgetfulness, a
lack of understanding of treatment benefits, complicated
regimens, and being away from their medications were
consistent barriers to adherence across developed and
developing nations. More common to developing settings
were issues of access, including financial constraints and a
disruption in access to medications. While there is a
tremendous paucity of qualitative research in developing
settings, our findings indicate that many barriers to adher-
ence can be addressed with patients through discussion and
education regarding treatment benefits to health. In devel-
oping settings, access to medications is the greatest concern.
Indeed, discussion in both economic settings may alleviate
patients’ suspicions regarding treatment and address prac-
Table 6. Extended.
Countries Reference Daily Schedules
Disruptions
in Daily
Routine/
Chaotic Life
Inconvenient/
Difficult to
Incorporate
Work/Family/
Caregiving
Responsibilities
Dietary
Requirements
Difficult
to Balance
Fell Asleep
Developed countries Ammassari, 2001[56]  
Brook, 2001[55]  
Catz, 2000[58]  
Chesney, 20[59]   
Eldred, 1998[61]  
Erlen, 2002[62] 
Ferguson, 2002[4]  
Gibb, 2003[65]   
Giacomet, 2003[64] 
Harzke, 2004[66]
Heckman, 2004[67]  
Horne, 2004[69] 
Johnson, 2003[70] 
Kalichman, 1999[71]  
Kerr, 1999[72]   
Kleeberger, 2001[73]  
Marhefka, 2004[74]    
Moatti, 2000[75] 
Mohammed, 2004[76]   
Mostashari, 1998[79]
Muma, 1995[80] 
Murphy, 2003[81] 
Nieuwkerk, 2001[83]  
Palmer, 2003[84]  
Reddington, 2000[86] 
Reynolds,2004[87]   
Savini, 2003[88] 
Schneider, 2004[89]
Siegel, 2000[90]
Simoni, 2002[91]
Spire, 2002[92] 
Stein, 2000[93]  
Tucker, 2004[95] 
Wagner, 2004[97] 
Walsh, 2001[98]   
Weidle, 1999[99]
Wilson, 2001[100]  
Developing countries Byakika-Tusiime, 2005[57]
Cupsa, 2000[60]
Fassinou, 2004[63]
Hofer, 2004[68]
Molassiotis, 2002[77]  
Monreal, 2002[78] 
Nachega, 2004[82] 
Pinheiro, 2002[85] 
Stout, 2004[94]  
van Oosterhout, 2005[96]
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tical barriers to improve adherence. This study should also be
used to guide the development of interventions aiming to
improve adherence in any setting.
This study has several important strengths. The methods we
employed to tabulate these findings come from a multi-step
process. We first systematically identified qualitative and
quantitative studies examining the questions. We then
extracted the themes from the qualitative studies and
determined which of them were sampled in the quantitative
studies. Finally, we synthesized the available quantitative data.
By systematically determining the existence and prevalence
of barriers in multiple qualitative and quantitative studies, we
believe that stronger inferences can be made into patient-
related adherence obstacles and facilitators. We have pre-
viously demonstrated that surveys benefit from systematically
examining qualitative studies, as this improves content
validity [13,101]. To this end, our review of qualitative studies
identified several key themes addressing barriers to adher-
ence that were not examined in larger quantitative studies.
The presence of barriers in more than one qualitative study,
consisting of populations of patients representing different
patient populations, supports the conclusion that these
barriers are somewhat applicable. Our meta-analysis of
survey data is a relatively new process that we have previously
Table 6. Extended.
Countries Reference Daily Schedules
Being Away
from Home/
Not Carrying Meds/
Storage Concerns
Too Busy/
Distracted
No Time
to Refill/
Pharmacy
Problems
Middle of
the Day/
Early Morning
Dose
Difficult to
Travel to
Appointments
Developing countries Ammassari, 2001[56] 
Brook, 2001[55] 
Catz, 2000[58]   
Chesney, 20[59] 
Eldred, 1998[61]  
Erlen, 2002[62]  
Ferguson, 2002[4]    
Gibb, 2003[65]  
Giacomet, 2003[64]
Harzke, 2004[66]
Heckman, 2004[67]
Horne, 2004[69]
Johnson, 2003[70]
Kalichman, 1999[71]  
Kerr, 1999[72]  
Kleeberger, 2001[73]   
Marhefka, 2004[74]     
Moatti, 2000[75]  
Mohammed, 2004[76]   
Mostashari, 1998[79]
Muma, 1995[80]
Murphy, 2003[81]  
Nieuwkerk, 2001[83] 
Palmer, 2003[84]  
Reddington, 2000[86]  
Reynolds,2004[87]   
Savini, 2003[88]
Schneider, 2004[89]
Siegel, 2000[90]
Simoni, 2002[91]   
Spire, 2002[92]  
Stein, 2000[93]  
Tucker, 2004[95]  
Wagner, 2004[97]
Walsh, 2001[98]   
Weidle, 1999[99] 
Wilson, 2001[100] 
Developed countries Byakika-Tusiime, 2005[57]   
Cupsa, 2000[60] 
Fassinou, 2004[63]  
Hofer, 2004[68]
Molassiotis, 2002[77]   
Monreal, 2002[78] 
Nachega, 2004[82]  
Pinheiro, 2002[85] 
Stout, 2004[94]   
van Oosterhout, 2005[96] 
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demonstrated [102,103], and can permit stronger inferences
into the generalizability of our findings. Finally, our criteria
to assess the quality of both qualitative studies and surveys
are a new contribution to the methodological literature.
Recognizing that the absence of reporting particular meth-
odological criteria may not reflect what was actually
conducted during a study [104], we invite discussion
regarding the relative usefulness and applicability of these
criteria.
This work has several limitations. We aimed to reduce
reviewer bias by conducting abstraction independently, in
duplicate. We cannot, however, know to what extent we may
miss themes or to what extent reporting bias of the original
report may have contributed. We emphasize that our
methodology is specific but not sensitive for identifying
themes. Reporting bias in the included manuscripts may have
limited our ability to identify all barriers and facilitators to
adherence. A broad range of economic and social conditions
fall under the Human Development Index. It would wrong to
assume that all individuals living in a HDI-categorized
‘‘developed’’ nation are in a better economic situation than
all individuals living in a ‘‘developing’’ nation. Detailed
information pertaining to this was rarely available in the
original reports included in this review. It is possible that
Table 6. Extended.
Countries Reference Interpersonal Factors
Negative View/
Lack of Trust
in Provider
Social Isolation Negative Social
Support
Negative Publicity/
Historical Knowledge
Developed countries Ammassari, 2001[56]
Brook, 2001[55]
Catz, 2000[58] 
Chesney, 20[59]
Eldred, 1998[61]
Erlen, 2002[62] 
Ferguson, 2002[4]  
Gibb, 2003[65]
Giacomet, 2003[64]
Harzke, 2004[66]  
Heckman, 2004[67]
Horne, 2004[69]
Johnson, 2003[70]
Kalichman, 1999[71]
Kerr, 1999[72]
Kleeberger, 2001[73] 
Marhefka, 2004[74]
Moatti, 2000[75]
Mohammed, 2004[76]
Mostashari, 1998[79]
Muma, 1995[80] 
Murphy, 2003[81]
Nieuwkerk, 2001[83]
Palmer, 2003[84]
Reddington, 2000[86] 
Reynolds,2004[87]
Savini, 2003[88]
Schneider, 2004[89]
Siegel, 2000[90]  
Simoni, 2002[91]
Spire, 2002[92] 
Stein, 2000[93]
Tucker, 2004[95]   
Wagner, 2004[97]
Walsh, 2001[98] 
Weidle, 1999[99]
Wilson, 2001[100]
Developing countries Byakika-Tusiime, 2005[57]
Cupsa, 2000[60]
Fassinou, 2004[63]
Hofer, 2004[68] 
Molassiotis, 2002[77]
Monreal, 2002[78]
Nachega, 2004[82]
Pinheiro, 2002[85]
Stout, 2004[94]
van Oosterhout, 2005[96]
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surveys used in developing nations were similar to surveys
used in developed nations. However, the validity of these
surveys in developing settings may not be appropriate, and
we press for further qualitative research on this topic.
Detailed population descriptions (e.g., education level) and
the regional conditions from which this study is produced
(e.g., gross national product) would benefit interpretation of
future studies in this field. There are several interpretations
of appropriate adherence and execution of drug regimens.
We did not evaluate patients’ perceptions of what ‘‘adher-
ence’’ mean to them, whether it meant acceptance, execution,
or persistence of drug therapy [105]. In our meta-analyses of
pooled survey data, we found large heterogeneity (as
displayed by the I2 values in Figures 2 and 3), indicating
large variation between the surveys. Very little methodolog-
ical literature deals with pooling proportions, and our
findings call for further exploration to determine the
importance of this heterogeneity. Finally, there were few
studies in developing countries that studied early adopters to
antiretroviral therapy. These individuals may not be repre-
sentative of the larger epidemic and may not have experi-
enced longer-term side effects of therapy.
Table 7. Facilitators Reported in Quantitative Studies (Surveys)
Countries Reference Patient Related Medication/Regimen Beliefs
Self-Meaning/
Self-Efficacy
Medication
Takes
Priority over
Substance Use
Accepted
HIV Status/
Learned to
Manage
Seeing
Positive
Results
Understand
Need
for
Compliance
Belief in Efficacy
of Drugs/
Faith in
Treatment
Simple
Regimen
Developed countries Ammassari 2001[56]
Brook, 2001[55]
Catz, 2000[58]
Chesney, 2000[59]
Erlen, 2002[62]
Eldred, 2002[61]
Ferguson, 2002[4]
Gibb, 2003[65]
Giacomet, 2003[64]
Harzke, 2004[66] 
Heckman, 2004[67]
Horne, 2004[69]
Johnson, 2003[70]    
Kalichman, 1999[71]
Kerr, 1999[72]
Kleeberger, 2001[73]
Marhefka, 2004[74]
Moatti, 2000[75]
Mohammed, 2004[76]
Mostashari, 1998[79]  
Muma, 1995[80] 
Murphy, 2003[81]
Nieuwkerk, 2001[83]
Palmer, 2003[84]
Reddington, 2000[86]
Reynolds, 2004[87]  
Savini, 2003[88]
Schneider, 2004[89]   
Siegel, 2000[90]  
Simoni, 2002[91]
Spire, 2002[92]
Stein, 2000[93]
Tucker, 2004[95]
Wagner, 2004[97]    
Walsh, 2001[98]
Weidle, 1999[99]
Wilson, 2001[100]
Developing countries Byakika-Tusiime, 2005[57]
Cupsa, 2000[60]
Fassinou, 2004[63]
Hofer, 2004[68] 
Molassiotis, 2002[77]
Montreal, 2002[78]
Nachega, 2004[82]
Pinheiro, 2002[85]  
Stout, 20004[94]
Van Oosterhout, 2005[96]
doi:10.1371/journal.pmed.0030438.t007
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It is important to note that the qualitative studies
generated a richer spectrum of barriers and facilitators than
did the quantitative studies. Qualitative studies are superior
at identifying patient-important barriers and facilitators. We
would submit that the ideal study of adherence would be one
that occurs across several phases and incorporates both
qualitative and quantitative elements. For example, to avoid
biasing one’s investigation with a priori assumptions about
what may be important factors relating to adherence in a
given population, it is logical to commence a study with
qualitative research, thereby allowing the local population to
tell the researchers what they believe to be important
barriers, rather than the reverse. By using questionnaires
developed in settings that are economically or culturally
foreseeably different, the surveys force respondents to answer
potentially irrelevant questions.
Clearly, the evidence base for barriers and facilitators of
adherence is far richer from developed countries than from
developing countries. In our analysis we found only two
qualitative studies published from developing nation settings.
This is sadly paradoxical, given that the vast majority of HIV/
AIDS patients live in the developing world, and over the
coming decades will constitute a growing proportion, and
probably the majority, of the world’s HAART recipients.
Table 7. Extended.
Countries Reference Daily Schedules Interpersonal Relationships
Have
Fixed
Routine
Use
Reminder
Tools
Having Social
Support/
Open with Friends
and Family
Good
Relationship
with
Provider
Living for
Someone
Part of
Decision
Making with
Provider
Family/
Friends
Help
Remind
Developed countries Ammassari 2001[56]
Brook, 2001[55]
Catz, 2000[58]
Chesney, 2000[59]
Erlen, 2002[62]
Eldred, 2002[61]
Ferguson, 2002[4]
Gibb, 2003[65]
Giacomet, 2003[64]
Harzke, 2004[66]  
Heckman, 2004[67]
Horne, 2004[69]
Johnson, 2003[70]  
Kalichman, 1999[71]
Kerr, 1999[72]
Kleeberger, 2001[73]
Marhefka, 2004[74]
Moatti, 2000[75]
Mohammed, 2004[76]
Mostashari, 1998[79]   
Muma, 1995[80]
Murphy, 2003[81]
Nieuwkerk, 2001[83]
Palmer, 2003[84]
Reddington, 2000[86]
Reynolds, 2004[87] 
Savini, 2003[88]
Schneider, 2004[89]  
Siegel, 2000[90]
Simoni, 2002[91]
Spire, 2002[92]
Stein, 2000[93]
Tucker, 2004[95]
Wagner, 2004[97]  
Walsh, 2001[98]
Weidle, 1999[99]
Wilson, 2001[100]
Developing countries Byakika-Tusiime, 2005[57]
Cupsa, 2000[60]
Fassinou, 2004[63]
Hofer, 2004[68]
Molassiotis, 2002[77]
Montreal, 2002[78]
Nachega, 2004[82]
Pinheiro, 2002[85]
Stout, 20004[94]
Van Oosterhout, 2005[96]
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Consequently, we see further research on HAART adherence
in developing countries that incorporates both qualitative
and quantitative elements as a priority.
Our findings should influence adherence program delivery
systems in developing settings. We found that issues such as
fear of disclosure, suspicions about treatment, forgetfulness,
and irregular supply were important barriers identified by
large proportions of the populations studied. It seems
appropriate that before mandating any adherence program,
such as disclosure or accompagnateurs, opportunities should
be provided for individuals who require opting out [106,107].
Further, in developing settings, the reliability of medication
access is an important adherence barrier that individuals
have little opportunity to facilitate. Patient-level adherence
can be determined only when a steady supply of medication
exists.
We identified a broad range of barriers and facilitators to
adherence. These barriers should be inferred as guides for
interventional research to improve adherence rates. Given
the many factors tabulated in this review, clinicians should
use this information to engage in open discussion with
patients to promote adherence and identify barriers and
facilitators within their own populations. The methodology
we used to pool the quantitative data is novel and may prove
a useful methodological tool for generalizing patient-impor-
tant issues.
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Editors’ Summary
Background. The World Health Organization has estimated that in 2005,
about 38 million people worldwide were living with HIV/AIDS; the
mortality caused by HIV/AIDS is very high. Antiretroviral drugs are
effective at controlling the disease and extending life span. However, it is
important for people to stick to the drug regimens exactly in order to
keep levels of HIV low, prevent it from becoming resistant to drugs, and
stop the illness from progressing. However, many people find it very
difficult to take antiretroviral drugs precisely as they should. There is
already some evidence from research studies on the reasons why this is
the case. There are two different research approaches taken by these
studies: ‘‘qualitative’’ methods, which try to find out about attitudes and
behaviors using focus groups, interviews, or other techniques; and
‘‘quantitative’’ methods, which try to find out about peoples’ opinions
and experience using surveys with set questions for the participants to
answer, and then count the different responses.
Why Was This Study Done? The investigators wanted to put together
all of the available evidence from published research studies (called
doing a ‘‘systematic review’’) on which factors affected people’s
adherence to antiretroviral drugs. They wanted to do a systematic
review because it is thought to be a very rigorous way of appraising all
the available evidence (although there is considerable debate about the
value of using such a method to analyze the results of qualitative
research).
What Did the Researchers Do and Find? The study team searched
biomedical literature databases as well as conference abstracts and
research registries using a defined set of search queries. They screened
all the scientific papers they found; those reporting results of original
research into factors affecting antiretroviral adherence were then
analyzed in more detail. 84 relevant studies were identified, of which
37 used ‘‘qualitative’’ methods (focus groups, interviews, open-ended
questioning) and 47 used ‘‘quantitative’’ methods (surveys). Most of
these studies had been carried out in the developed world. Then, the
researchers extracted the factors affecting adherence from the original
studies, which could be either ‘‘positive’’ factors (helping adherence) or
‘‘negative’’ ones (making adherence more difficult). They classified the
factors into four key themes: ‘‘patient related’’ (e.g., seeing positive
results, fear of disclosure, being depressed); ‘‘beliefs about medication’’
(e.g., faith in how well the drugs worked, side effects); ‘‘daily schedules’’
(e.g., using reminder tools, disruptions to routine); and ‘‘interpersonal
relationships’’ (e.g., trusting relations with health-care provider; social
isolation).
Many barriers to adherence were common to both developed and
developing settings. Some factors were unique to the studies conducted
in the developing world, such as financial constraints and problems with
traveling to get access to treatment. Fear of disclosure was an important
barrier identified in many of the studies.
What Do These Findings Mean? The researchers combined the results
of many different studies and identified factors that help or obstruct
adherence to antiretroviral treatment. By identifying influences common
to the different settings, greater weight can be placed on the factors that
were identified. Only 12 of the studies included in this research were
from the developing world, where the majority of HIV/AIDS patients live;
hence more work is needed to examine and address the factors
influencing antiretroviral adherence in these parts of the world. This
study provides researchers and health policy makers with a starting point
for changes that might help to ensure greater adherence to antiretroviral
treatment.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030438.
 Medline Plus information on AIDS medicines (Medline Plus is a service
of the US National Library of Medicine and the National Institutes of
Health)
 Joint United Nations Programme on HIV/AIDS has information about
the state of the HIV/AIDS epidemic worldwide
 The World Health Organization has an HIV/AIDS program site
providing comprehensive information on the HIV/AIDS epidemic
worldwide
 The World Health Organization pages on antiretroviral therapy
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